Multiple Myeloma
Showing NaN - NaN of 91
Multiple Myeloma Trial in Spain, United States (BB2121, CC-220, BMS-986405)
Recruiting
- Multiple Myeloma
- BB2121
- +2 more
-
Birmingham, Alabama
- +33 more
Jan 26, 2023
Multiple Myeloma Trial in Worldwide (Selinexor, Dexamethasone)
Completed
- Multiple Myeloma
-
Birmingham, Alabama
- +60 more
Jan 24, 2023
Collection of Tissue Samples for Cancer Research
Recruiting
- Neoplasms
- +3 more
- Biopsy
-
Atlanta, Georgia
- +9 more
Jan 23, 2023
Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma Trial in Korea, Republic of, United States (Tiragolumab,
Active, not recruiting
- Multiple Myeloma
- +2 more
- Tiragolumab
- +3 more
-
Denver, Colorado
- +12 more
Jan 19, 2023
Multiple Myeloma Trial in Worldwide (JNJ-68284528, Pomalidomide, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- JNJ-68284528
- +4 more
-
Birmingham, Alabama
- +87 more
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab IV, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Daratumumab IV
- +3 more
-
Birmingham, Alabama
- +211 more
Jan 17, 2023
Multiple Myeloma Trial in Worldwide (Placebo, Ixazomib)
Multiple Myeloma Trial in Worldwide (Modakafusp alfa, Lenalidomide, Bortezomib)
Recruiting
- Multiple Myeloma
- Modakafusp alfa
- +5 more
-
Little Rock, Arkansas
- +53 more
Jan 12, 2023
Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,
Recruiting
- Waldenstrom Macroglobulinemia
- +8 more
- Iopofosine I 131 single dose
- +2 more
-
Redlands, California
- +42 more
Dec 30, 2022
Multiple Myeloma Trial in Worldwide (bb2121, Daratumumab, Pomalidomide)
Active, not recruiting
- Multiple Myeloma
- bb2121
- +8 more
-
Birmingham, Alabama
- +59 more
Dec 13, 2022
Multiple Myeloma Trial in United States (Belantamab mafodotin)
Recruiting
- Multiple Myeloma
- Belantamab mafodotin
-
San Francisco, California
- +5 more
Dec 9, 2022
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma Trial in Baltimore (Fludarabine,
Completed
- Myelodysplastic Syndrome
- +13 more
- Fludarabine
- +4 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nov 2, 2022
Multiple Myeloma Trial in United States (procedure, drug, biological)
Completed
- Multiple Myeloma
- Tumor Cell Collection
- +6 more
-
San Francisco, California
- +14 more
Jul 11, 2022
Multiple Myeloma Trial in Worldwide (Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder)
Active, not recruiting
- Multiple Myeloma
- Belantamab mafodotin frozen liquid
- Belantamab mafodotin lyophilized powder
-
New Haven, Connecticut
- +58 more
Jul 27, 2022
Multiple Myeloma Trial in Greece, Korea, Republic of, United States (Belantamab mafodotin)
Recruiting
- Multiple Myeloma
- Belantamab mafodotin
-
Tucson, Arizona
- +21 more
Jul 20, 2022
Multiple Myeloma Trial in Worldwide (BL-8040 1.25mg/kg + G-CSF, Placebo +G-CSF)
Active, not recruiting
- Multiple Myeloma
- BL-8040 1.25mg/kg + G-CSF
- Placebo +G-CSF
-
Los Angeles, California
- +17 more
Jun 14, 2022
Developing Myeloma in a High-Risk Screened Population (PROMISE)
Recruiting
- Multiple Myeloma
- Sample of Blood
-
Baltimore, Maryland
- +2 more
Mar 22, 2022
Multiple Myeloma Trial in Baltimore (Ciforadenant, daratumumab)
Completed
- Multiple Myeloma
-
Baltimore, MarylandThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mar 9, 2022